Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.
de Arriba de la Fuente F, Durán MS, Álvarez MÁ, Sanromán IL, Dios AM, Ríos Tamayo R, García R, González MS, Prieto E, Bárez A, Escalante F, Tejedor A, Ballesteros M, Cabañas V, Capote FJ, Couto C, Garzón S, González-Pardo M, Mateos Manteca MV. de Arriba de la Fuente F, et al. Semin Hematol. 2018 Oct;55(4):189-196. doi: 10.1053/j.seminhematol.2017.09.002. Epub 2017 Oct 13. Semin Hematol. 2018. PMID: 30502846 Review.
[Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC, León-Villar J, de Arriba de la Fuente F, Moreno Belmonte MJ, Iranzo Fernández MD. Titos-Arcos JC, et al. Among authors: de arriba de la fuente f. Farm Hosp. 2012 Jul-Aug;36(4):275-81. doi: 10.1016/j.farma.2011.06.019. Epub 2011 Nov 23. Farm Hosp. 2012. PMID: 22115856 Free article. Spanish.
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Kaiser M, et al. Among authors: de arriba de la fuente f. Ann Hematol. 2020 Aug;99(8):1793-1804. doi: 10.1007/s00277-020-04149-5. Epub 2020 Jul 1. Ann Hematol. 2020. PMID: 32613281 Free PMC article. Clinical Trial.
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups. Paiva B, et al. Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11. Blood. 2016. PMID: 26755711 Free article. Clinical Trial.
Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT).
Hernández-Fernández A, Oñate-Sánchez RE, Cabrerizo-Merino MC, de Arriba-de la-Fuente F, Heras-Fernando I, Vicente-García V. Hernández-Fernández A, et al. Among authors: de arriba de la fuente f. Med Oral Patol Oral Cir Bucal. 2012 Jan 1;17(1):e94-e101. doi: 10.4317/medoral.16997. Med Oral Patol Oral Cir Bucal. 2012. PMID: 22157660 Free PMC article.
Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study.
de Arriba de la Fuente F, Gironella Mesa M, Hernández García MT, Soler Campos JA, Herráez Rodríguez S, Moreno Belmonte MJ, Regueiro López T, González-Pardo M, Casanova Espinosa M, On Behalf Of The Carinae Study Investigators. de Arriba de la Fuente F, et al. Pharmaceuticals (Basel). 2024 Sep 26;17(10):1272. doi: 10.3390/ph17101272. Pharmaceuticals (Basel). 2024. PMID: 39458913 Free PMC article.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Facon T, et al. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3. N Engl J Med. 2024. PMID: 38832972 Clinical Trial.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators. Dimopoulos MA, et al. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828951 Clinical Trial.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
13 results